NEWS & DEVELOPMENT
Impactful technology
December 2019
HelixBind awarded $4M of additional funding by CARB-X to continue development of RaPID diagnostic platform.
MARCH 2018
HelixBind awarded up to $2M from CARB- X to combat the rise of antimicrobial resistant pathogens.
SEPTEMBER 2017
HelixBind closes $3M in Series-A financing
AUGUST 2017
HelixBind awarded a $2.0M Phase II SBIR from the National Institutes of Health (NIH) to further development of a culture-free, sample-to-answer test for detecting and identifying microbial pathogens prevalent in neonatal sepsis.
APRIL 2017
USPTO issues HelixBind patent US 14/402,028 covering methods and compositions of matter for diagnosing sepsis
AUGUST 2016
HelixBind awarded a $2.4M Direct-to-Phase II SBIR from the National Institutes of Health (NIH) to automate its sample-to-answer test for discriminating among bacterial pathogens
MARCH 2016
HelixBind published its work, completed in collaboration with Tufts Medical Center and Sloan Memorial Kettering Cancer Center demonstrating successful implementation of its novel sample-to-answer Core Pathogen Identification (C/PID) platform for identifying bloodstream infections directly from patient specimens in under 2.5 hours.
JULY 2015
HelixBind awarded $1.5M Phase II SBIR from the National Institutes of Health (NIH)
MARCH 2014
HelixBind closes $1.65M seed financing